Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study
Int. braz. j. urol
; 44(5): 892-899, Sept.-Oct. 2018. tab, graf
Article
em En
| LILACS
| ID: biblio-975631
Biblioteca responsável:
BR1.1
ABSTRACT
ABSTRACT Purpose:
The purpose of our study was to evaluate the clinical impact of 68Ga-PSMA PET / CT in the setting of biochemical recurrence of prostate cancer. Materials andMethods:
We retrospectively evaluated 125 prostate cancer patients submitted to the 68Ga-PSMA PET / CT due to biochemical recurrence. The parameters age, Gleason score, PSA levels, and the highest SUVmax were correlated to potential treatment changes. The highest SUVmax values were correlated with age and Gleason score. The median follow-up time was 24 months.Results:
68Ga-PSMA PET / CT led to a treatment change in 66 / 104 (63.4%) patients (twenty-one patients were lost to follow-up). There was a significant change of treatment plan in patients with a higher Gleason score (P = 0.0233), higher SUVmax (p = 0.0306) and higher PSA levels (P < 0.0001; median PSA = 2.55 ng / mL).Conclusion:
68Ga-PSMA PET / CT in prostate cancer patients with biochemical recurrence has a high impact in patient management.Palavras-chave
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Oligopeptídeos
/
Neoplasias da Próstata
/
Ácido Edético
/
Antígeno Prostático Específico
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
/
Recidiva Local de Neoplasia
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
Int. braz. j. urol
Assunto da revista:
UROLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Brasil